• Disabling Tumor Extracellular Vesicles to Inhibit Metastasis

  2026-05-29

  This study introduces a lipidated nanophotosensitizer capable of tracing and disabling tumor extracellular vesicles (TEVs), offering a dual approach to suppress both tumor growth and metastasis. The work demonstrates that targeted photodynamic therapy can impede TEV-mediated communication, addressing a major bottleneck in current metastatic cancer treatments.

• Cy5 NHS ester(Et): Technical Guidance for Fluorescent Labeli

  2026-05-29

  Cy5 NHS ester(Et) enables efficient, water-soluble fluorescent labeling of primary amines in proteins and biomolecules for detection workflows in immunofluorescence, flow cytometry, and fluorescence microscopy. It is unsuitable for ethanol-based protocols and should not be stored in solution for extended periods. This article outlines practical use, limitations, and troubleshooting for optimal results.

• Gemcitabine: Applied Workflows and Troubleshooting in Cancer

  2026-05-28

  Gemcitabine, a potent DNA synthesis inhibitor, is pivotal for dissecting DNA damage responses and apoptosis in cancer models. This article presents stepwise protocol enhancements, experimental caveats, and troubleshooting tips that maximize Gemcitabine’s value in translational oncology, informed by recent metabolic insights and robust performance benchmarks.

• Sabutoclax as a Pan-Bcl-2 Inhibitor: Systems Biology Insight

  2026-05-28

  Explore how Sabutoclax, a potent pan-Bcl-2 inhibitor, enables systems-level insights into apoptosis induction in cancer cells. This article uniquely integrates quantitative drug response frameworks and practical assay choices, advancing both experimental design and translational oncology.

• Grazoprevir/Elbasvir: Redefining HCV Genotype 1 & 4 Therapy

  2026-05-27

  This review assesses the clinical impact of the fixed-dose combination of grazoprevir (MK-5172 hydrate) and elbasvir for hepatitis C virus (HCV) infection, especially genotypes 1 and 4. The study highlights the regimen’s high efficacy, broad patient applicability—including coinfection and renal impairment—and advances in tolerability and treatment simplicity.

• VE-822 ATR Inhibitor: Enhancing Chemoradiotherapy in PDAC Mo

  2026-05-27

  VE-822, a highly potent ATR inhibitor, is redefining DNA damage response research and radiosensitization in pancreatic ductal adenocarcinoma (PDAC). This article details robust experimental workflows, practical troubleshooting, and emerging use-cases—especially where iPSC-based platforms guide drug selection in ultrarare contexts.

• VE-822 ATR Inhibitor: Precision Tools for DDR Assay Innovati

  2026-05-26

  Explore how VE-822, a potent ATR inhibitor, is transforming DNA damage response (DDR) assay development and personalized cancer research. This in-depth review reveals advanced methodological insights and practical assay recommendations beyond existing protocol guides.

• CBD Attenuates Orofacial Inflammatory Pain via Endocannabino

  2026-05-26

  This study demonstrates that cannabidiol (CBD) robustly reduces both the sensory and emotional components of orofacial inflammatory pain in mice. By elucidating CBD’s mechanisms—namely, the modulation of endocannabinoid and serotonergic pathways—the research provides a mechanistic rationale for targeting FAAH and endocannabinoid signaling in pain and mood disorder models.

• Poly(I:C): Driving Precision in Innate Immunity and Translat

  2026-05-25

  This thought-leadership article explores how Poly(I:C), a synthetic double-stranded RNA analog and potent TLR3 agonist, is redefining the boundaries of immune system activation, dendritic cell maturation, and translational research. Blending mechanistic insights with protocol guidance and a strategic outlook, it guides researchers in leveraging Poly(I:C) for robust interferon induction, disease modeling, and next-generation immunotherapeutics.

• Dovitinib (TKI-258): Applied Workflows for Cancer Research

  2026-05-25

  Dovitinib (TKI-258) empowers advanced cancer research by enabling robust inhibition of key RTKs, optimizing apoptosis induction in challenging models like multiple myeloma and hepatocellular carcinoma. This guide delivers actionable experimental protocols, troubleshooting strategies, and practical insights—bridging recent mechanistic breakthroughs with reliable, reproducible bench workflows.

• Gemcitabine in Cancer Research: Protocols, Workflows & Insig

  2026-05-24

  Gemcitabine’s precision as a DNA synthesis inhibitor makes it a cornerstone for apoptosis and DNA damage response assays in cancer research. This guide translates cutting-edge findings and best practices into actionable protocols, troubleshooting, and strategic applications—empowering researchers to harness Gemcitabine’s full potential with confidence.

• Dacarbazine: Applied Workflows for Antineoplastic Chemothera

  2026-05-23

  Dacarbazine is a cornerstone antineoplastic chemotherapy drug, pivotal for DNA alkylation studies across malignant melanoma, Hodgkin lymphoma, and sarcoma research. This article delivers practical protocols, troubleshooting, and workflow innovations—bridging frontline bench science with data-driven insights for reproducibility and translational impact.

• Optimizing ARCA-Capped mRNA Synthesis: Insights with HyperSc

  2026-05-22

  Discover how the HyperScribe Co-transcription mRNA Synthesis Kit Plus streamlines ARCA capped mRNA synthesis for advanced immunotherapy and functional genomics. This in-depth analysis explores unique technical strategies, scientific rationale, and protocol best practices.

• Rucaparib (AG-014699) in DNA Damage Response: Protocols & In

  2026-05-22

  Rucaparib (AG-014699) is redefining DNA damage response research by enabling precision radiosensitization, especially in PTEN-deficient and ETS fusion-expressing prostate cancer models. This article delivers actionable workflows, troubleshooting guidance, and integrates novel reference findings to maximize its application in advanced cancer biology.

• Improved In Vitro Evaluation of Antineoplastic Drug Response

  2026-05-21

  Schwartz's dissertation introduces a refined approach for distinguishing between proliferation arrest and cell death in cancer drug response assays. By delineating relative and fractional viability metrics, this work enhances the mechanistic resolution and reliability of in vitro antineoplastic drug testing, with implications for more predictive translational oncology workflows.

15144 records 1/1010 page Next 12345 下5页 Last page